“According to a new report published by Introspective Market Research, Preimplantation Genetic Diagnosis Market by Technology, Application, and End User, The Global Preimplantation Genetic Diagnosis Market Size Was Valued at USD 57.3 Million in 2023 and is Projected to Reach USD 113.6 Million by 2032, Growing at a CAGR of 7.9% From 2024–2032.”

Preimplantation Genetic Diagnosis (PGD) is an advanced genetic testing technique used alongside in vitro fertilization (IVF) to screen embryos for specific genetic disorders before implantation. This technology enables the detection of chromosomal abnormalities and inherited genetic conditions, helping reduce the risk of genetic diseases and improve pregnancy outcomes.

PGD offers significant advantages over traditional prenatal diagnostic methods by enabling early-stage detection without affecting an ongoing pregnancy. It is widely adopted in fertility clinics to support couples with a history of genetic disorders, recurrent miscarriages, or advanced maternal age. The increasing success rates of IVF procedures further support the adoption of PGD worldwide.

Growing awareness about genetic screening, rising infertility rates, and continuous advancements in molecular diagnostics are accelerating market growth. Additionally, expanding applications in personalized medicine and preventive healthcare are positioning PGD as a critical component of modern reproductive health services.

Market Segmentation

The Preimplantation Genetic Diagnosis Market is segmented into Technology, Application, and End User.
By Technology, the market is categorized into Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), Next-Generation Sequencing (NGS), and Others.
By Application, the market is categorized into Aneuploidy Screening, Single-Gene Disorders, HLA Typing, and Sex Selection.
By End User, the market is categorized into Fertility Clinics, Hospitals, and Diagnostic Laboratories.

Growth Driver

The primary growth driver of the Preimplantation Genetic Diagnosis market is the rising prevalence of genetic disorders and infertility worldwide. Increasing maternal age, lifestyle-related health issues, and hereditary disease risks have heightened the demand for advanced reproductive technologies. PGD allows early detection of genetic abnormalities, significantly improving IVF success rates and reducing emotional and financial burdens on families. Moreover, continuous improvements in genomic technologies, such as NGS, have enhanced diagnostic accuracy, reliability, and efficiency, further encouraging adoption among fertility specialists and healthcare providers globally.

Market Opportunity

A key market opportunity lies in the expanding adoption of PGD in emerging economies. Improved healthcare infrastructure, increasing fertility tourism, and growing awareness of genetic testing are opening new avenues for market players. Additionally, technological innovations that reduce testing costs and improve turnaround times are making PGD more accessible. Government initiatives supporting assisted reproductive technologies and rising investments in genomics research further create long-term growth potential for companies operating in the global Preimplantation Genetic Diagnosis market.

Detailed Segmentation

Preimplantation Genetic Diagnosis Market, Segmentation

Line below: The Preimplantation Genetic Diagnosis Market is segmented on the basis of Technology, Application, and End User.

Technology

The Technology segment is further classified into PCR, FISH, and NGS. Among these, the Next-Generation Sequencing (NGS) sub-segment accounted for the highest market share in 2023. NGS offers superior accuracy, high-throughput screening, and comprehensive chromosomal analysis, making it the preferred choice for fertility clinics. Its ability to detect multiple genetic abnormalities simultaneously has significantly improved embryo selection and IVF success rates, driving widespread adoption globally.

Application

The Application segment is further classified into Aneuploidy Screening, Single-Gene Disorders, and HLA Typing. Among these, the Aneuploidy Screening sub-segment accounted for the highest market share in 2023. This application is widely used to detect chromosomal abnormalities that can lead to implantation failure or miscarriage. Growing demand for healthy pregnancies and improved IVF outcomes continues to fuel growth in this segment.

Some of The Leading/Active Market Players Are-

• Illumina, Inc. (USA)
• Thermo Fisher Scientific Inc. (USA)
• Agilent Technologies, Inc. (USA)
• Natera, Inc. (USA)
• Roche Diagnostics (Switzerland)
• Abbott Laboratories (USA)
• BGI Genomics (China)
• CooperSurgical, Inc. (USA)
• Genea Biomedx (Australia)
• Invitae Corporation (USA)
• Oxford Gene Technology (UK)
• PerkinElmer, Inc. (USA)

and other active players.

Key Industry Developments

In March 2024, leading diagnostic companies expanded their PGD service offerings by integrating advanced NGS platforms.
This development improved test accuracy and reduced analysis time, enabling fertility clinics to offer faster and more reliable genetic screening services, thereby enhancing patient outcomes.

In October 2023, several fertility clinics across Asia-Pacific invested in PGD infrastructure to support rising IVF demand.
These expansions aimed to meet growing fertility tourism and local demand, strengthening the regional PGD market presence.

Key Findings of the Study

• NGS technology dominates the global market
• Aneuploidy screening is the leading application segment
• North America holds the largest market share
• Rising infertility and genetic disorders drive growth
• Technological advancements are shaping market trends

More Info:- https://introspectivemarketresearch.com/reports/preimplantation-genetic-diagnosis-market/

About Us

At Introspective Market Research Private Limited, we are a forward-thinking research consulting firm committed to driving growth in the Preimplantation Genetic Diagnosis Market. With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global Hormone Replacement Therapy Market industry.

📞 Contact Us

Introspective Market Research Pvt. Ltd.
Phone: +91-91753-37569
Email: sales@introspectivemarketresearch.com
Web: www.introspectivemarketresearch.com